This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosi…

Hereditary Leiomyomatosis and Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell Carcinoma+3 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04981509

Phase 1

Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)

This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosi…

Advanced Kidney CarcinomaAdvanced Renal Cell CarcinomaHereditary Leiomyomatosis and Renal Cell Carcinoma+6 more

~Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT07716735